Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07024784 2026-04-06

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2 Recruiting

377 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasms

NCT05415709 2026-02-11

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Phase EARLY_PHASE1 Recruiting

45 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06466382 2026-01-12

OVPrecision

Phase NA Recruiting

60 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT07322094 2026-01-07

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

Phase 1/2 Recruiting

60 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

970 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07022535 2025-07-02

PRESELECT-0

Phase 2 Recruiting

18 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07023484 2025-07-02

Preselect-1

Phase 2 Recruiting

126 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05737303 2025-02-11

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Phase 3 Recruiting

538 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06735326 2024-12-16

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

Phase 2 Recruiting

105 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05080556 2024-04-12

ACTOv

Phase 2 Recruiting

80 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Phase 2 Recruiting

167 enrolled

Gynecologic

Fallopian Tube Neoplasms

Clinical Trials

FRAmework-01

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

MRD

OVATION-3

MUIR

RAINFOL-01

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

OVPrecision

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

PRESELECT-0

Preselect-1

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

ACTOv

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)